反応 #165806
ord-f9c1f81aa5aa467d91329ae12d16c0b9
反応方程式
反応物
試薬
反応条件
後処理
- 1その他was flushed further with methanol (5 mL)
- 2濃縮The filtrate was concentrated in vacuo
- 3その他to leave a yellow/orange solid
- 4洗浄The cartridge was washed initially with methanol
- 5洗浄the product eluted with 2M ammonia in methanol solution over 4 fractions
- 6その他A yellow solid crystallised out of the filtrate which
- 7その他was isolated by filtration
実験手順
TFA (131.1 mg, 88.58 μL, 1.150 mmol) was added to a solution of tert-butyl N-[[3-[5-[3-amino-6-[4-(dimethylcarbamoyl)phenyl]pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]phenyl]methyl]carbamate (60 mg, 0.1150 mmol) in dichloromethane (2 mL) and the resulting solution stirred at room temperature overnight. The reaction mixture was passed through a bicarbonate cartridge, which was flushed further with methanol (5 mL). The filtrate was concentrated in vacuo to leave a yellow/orange solid. The solid was taken up in a mixture of methanol and dichloromethane and passed through an SCX cartridge. The cartridge was washed initially with methanol and then the product eluted with 2M ammonia in methanol solution over 4 fractions. A yellow solid crystallised out of the filtrate which was isolated by filtration to give the product (44 mg, 90% yield) 1H NMR (400 MHz, DMSO) d 2.98 (m, 6H), 3.87 (s, 2H), 7.55 (m, 2H), 7.59-7.66 (m, 2H), 7.81 (br s, 2H), 8.00 (m, 1H), 8.17 (m, 3H) and 8.99 (s, 1H) ppm; MS (ES+) 416.26